Merck & Co. Inc.

Merck & Co. Inc.

Merck & Co develops, manufactures and markets a range of pharmaceutical and biologic products focused on prescription drugs.

Stock Performance Snapshot

Buy

Analyst Rating

Analysts recommend buying Merck's stock with a target price of $101.62, indicating expected growth.

Excellent

Financial Health

Merck is producing strong profits, cash flow, and revenue, showing solid financial stability.

Average

Dividend

Merck's average dividend yield of 3.66% offers a decent return for dividend-seeking investors. If you invested $1000 you would be paid $36.20 a year in dividends (based on the last 12 months).

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring MRK

Global Pharma Titans | Brazil Healthcare Investment

Global Pharma Titans | Brazil Healthcare Investment

Brazil's large and innovative pharmaceutical market presents a significant area of interest for those looking at global healthcare trends. This basket provides exposure to leading US and EU-listed pharmaceutical and biotech companies with substantial operations, partnerships, or sales within Brazil.

Published: October 16, 2025

Explore Basket
Pharmaceutical Policy Shift Explained | Pricing Models

Pharmaceutical Policy Shift Explained | Pricing Models

The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.

Published: October 12, 2025

Explore Basket
Domestic Pharma Tariffs: What's Next for Investors

Domestic Pharma Tariffs: What's Next for Investors

The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.

Published: September 26, 2025

Explore Basket
Novo Nordisk Stock Risks: Healthcare Diversification

Novo Nordisk Stock Risks: Healthcare Diversification

As Africa's healthcare needs grow, demand for innovative treatments for chronic conditions like diabetes is on the rise. This basket offers potential exposure to this trend through leading global pharmaceutical and healthcare companies listed on US and EU exchanges.

Published: September 23, 2025

Explore Basket
Johnson & Johnson (Healthcare Diversification)

Johnson & Johnson (Healthcare Diversification)

As Nigeria's population seeks stable growth opportunities, the global healthcare sector offers a compelling theme for portfolio diversification. This basket provides exposure through a collection of US and EU-listed industry leaders in pharmaceuticals, medical devices, and consumer health.

Published: September 16, 2025

Explore Basket
Obesity Treatment (Pharma Giants vs Biotech Firms)

Obesity Treatment (Pharma Giants vs Biotech Firms)

Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.

Published: September 10, 2025

Explore Basket
Pharma's Pricing Pressure

Pharma's Pricing Pressure

In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.

Published: August 3, 2025

Explore Basket
Buffett's Billions: The Philanthropy Effect

Buffett's Billions: The Philanthropy Effect

Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.

Published: July 1, 2025

Explore Basket
Only Game In Town

Only Game In Town

These companies have achieved such dominance that they face little to no real competition in their markets. Our analysts have carefully selected businesses with unmatched market power, creating stability and sustained profitability that comes from being the only real choice in their sectors.

Published: June 20, 2025

Explore Basket
Sleep Well At Night Portfolio

Sleep Well At Night Portfolio

A collection of premium defensive stocks expertly selected by our analysts to help protect your investments during market turbulence. These industry giants offer stability through consistent earnings, reliable dividends, and proven resilience in any economic climate.

Published: June 18, 2025

Explore Basket
Market Indecision

Market Indecision

Find refuge from market volatility with these carefully selected companies providing essential goods and services. Our professional analysts have handpicked high-quality, dividend-paying stocks in defensive sectors that offer stability when economic futures look uncertain.

Published: June 18, 2025

Explore Basket
Companies That Give Back

Companies That Give Back

Channel your investments toward companies that make philanthropy a priority. These stocks have been carefully selected by our analysts for their commitment to giving back while building sustainable businesses that could deliver long-term value to investors.

Published: June 17, 2025

Explore Basket
Best In Class

Best In Class

Meet the true champions of the market. These carefully selected stocks represent the single most influential company in each economic sector, chosen by expert analysts for their market dominance and enduring competitive advantages.

Published: June 17, 2025

Explore Basket
Profit Sharers

Profit Sharers

These established market leaders don't just generate impressive profits—they're committed to sharing that wealth with you. Carefully selected by our analysts, these dividend powerhouses offer both reliable income streams and the stability of industry-leading businesses.

Published: June 17, 2025

Explore Basket
Mercury Retrograde

Mercury Retrograde

A collection of stable, essential businesses selected by financial experts to help protect your investments during market turbulence. These companies provide the goods and services people need every day, regardless of economic conditions.

Published: June 17, 2025

Explore Basket
Boomer Stocks

Boomer Stocks

Discover a collection of iconic, industry-leading companies with deep market roots and reliable dividend histories. These household names have been carefully selected by our analysts for their strong brands, steady cash flow, and potential for long-term stability.

Published: June 17, 2025

Explore Basket
Low Volatility Stocks

Low Volatility Stocks

Are you feeling seasick? Sail through calmer waters with these lower volatility investments. These handpicked stocks were carefully selected by our analysts for their history of stability and potential for consistent returns over time.

Published: May 21, 2025

Explore Basket
Pharma

Pharma

Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.

Published: May 6, 2025

Explore Basket

Why You’ll Want to Watch This Stock

📈

Stable cash generation

Merck's established medicines and vaccines often produce predictable revenues and support dividends, though performance can vary with product life cycles and competition.

R&D and pipeline

A deep pipeline, especially in oncology and infectious disease, is a potential long-term growth driver, but clinical and regulatory setbacks remain possible.

🌍

Global footprint matters

Broad international presence offers market diversification and scale benefits, while exposure to pricing debates, regulation and litigation can introduce volatility.

Why invest with Nemo?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

LLY

Eli Lilly and Company

Eli Lilly & Co is a global pharmaceutical company that develops, manufactures and markets human prescription drugs.

JNJ

Johnson & Johnson

Johnson & Johnson is a multinational conglomerate pharmaceutical, medical devices, and consumer packaged goods company.

ABBV

AbbVie Inc.

Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.

Frequently asked questions